India’s Bharat Biotech to sell $1 diarrhoea vaccine
June 6th, 2011 - 1:05 pm ICT by IANSHyderabad, June 6 (IANS) Leading bio-pharma company Bharat Biotech Monday announced that ROTAVAC®, India’s first indigenously developed rotavirus diarrohea vaccine, will be sold to global public markets, UN procurement agencies and governments the world over at a price of $1.
The Hyderabad-based firm hopes its new vaccine will help prevent part of the 500,000 child deaths each year caused due to rotavirus diarrhoea and improve access to better, affordable vaccines.
The company expects an India license for its vaccine in 2014 and World Health Organisation (WHO) prequalification in 2015 for supply to United Nations agencies.
The vaccine is currently undergoing Phase III clinical development for safety and efficacy in 8,000 subjects — one of the largest such clinical trials ever conducted in India, said a statement by the company.
“The key to our success of bringing down the cost of vaccine is our novel concept in vaccine development and innovative manufacturing processes with public health in mind,” said Bharat Biotech chairman and managing director Krishna Ella.
Ella recalled that in 2001 he had made a commitment to the Gates Foundation to develop and supply a novel rotavirus vaccine at $1 a dose. “We are extremely happy to honour that commitment,” he said.
Bharat Biotech’s rotavirus vaccine development project is a public-private partnership project.
It is between the company and the biotechnology department of the Indian government; Gates Foundation; Program for Appropriate Technologies in Health; Centers for Disease Control, US; National Institutes of Health (NIAID), USA; Society for Applied Studies, Translational Health Sciences Technology Institute, Indian Institute of Science, All India Institute of Medical Sciences, and Stanford University.
Bharat Biotech has an installed capacity of 300 million doses.
- Pune firm slashes pentavalent vaccine prices 60 percent - Jun 13, 2011
- Hyderabad foundation gets $100,000 grant for polio vaccine - May 10, 2012
- Bharat Biotech begins phase III trials of clot-busting drug - Feb 04, 2011
- Bharat Biotech vaccine doses touch one-billion mark - Feb 03, 2010
- 'Indian infants make 25 percent of global diarrhea deaths' - Mar 09, 2011
- Over 250 companies to participate in BioAsia 2012 - Feb 07, 2012
- National Institute of Immunology is developing anti- diarrhoea vaccine - Jun 12, 2009
- Bharat Biotech's rabies vaccine to touch 20 million doses - Oct 27, 2009
- Universal flu vaccine shows promise - Jun 08, 2011
- Vaccine makers to lobby for higher immunization coverage - Sep 15, 2010
- GVK BIO to support global consortium - May 16, 2011
- Vaccine manufacturers meet in Hyderabad - Sep 14, 2010
- Cuba to start clinical trials of pneumonia vaccine - May 04, 2012
- India to develop swine flu vaccine by 2010: Azad - Nov 24, 2009
- Indian biotech sector rebounds on global recovery - Jun 02, 2010
Tags: all india institute of medical sciences, appropriate technologies, biotechnology department, child deaths, foundation program, gates foundation, health sciences technology, india institute, indian institute of science, national institutes of health, novel concept, partnership project, pharma company, procurement agencies, public markets, public private partnership, rotavirus vaccine, stanford university, vaccine development, world health organisation